tetano
Editor, Senior Moderator
Obstet Gynecol
. 2023 May 11.
doi: 10.1097/AOG.0000000000005241. Online ahead of print. Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination
Malini B DeSilva[SUP] 1 [/SUP], Jacob Haapala, Gabriela Vazquez-Benitez, Thomas G Boyce, Candace C Fuller, Matthew F Daley, Darios Getahun, Simon J Hambidge, Heather S Lipkind, Allison L Naleway, Jennifer C Nelson, Kimberly K Vesco, Eric S Weintraub, Joshua T B Williams, Ousseny Zerbo, Elyse O Kharbanda
Affiliations
In this multisite, observational, matched cohort study of more than 80,000 pregnant people, receipt of an mRNA monovalent coronavirus disease 2019 (COVID-19) booster vaccination in pregnancy was not associated with increased risk for thrombocytopenia, myocarditis, venous thromboembolism, ischemic stroke, or other serious adverse events within 21 or 42 days after booster vaccination. The mRNA monovalent COVID-19 booster in pregnancy was associated with an increased risk for medically attended malaise or fatigue within 7 days of vaccination (adjusted rate ratio [aRR] 3.64, 95% CI 2.42-5.48) and lymphadenopathy or lymphadenitis within 21 days (aRR 3.25, 95% CI 1.67-6.30) or 42 days (aRR 2.18, 95% CI 1.33-3.58) of vaccination. Our findings are consistent with prior evaluations of the primary COVID-19 vaccine series and are reassuring with respect to COVID-19 booster vaccination in pregnancy.
. 2023 May 11.
doi: 10.1097/AOG.0000000000005241. Online ahead of print. Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination
Malini B DeSilva[SUP] 1 [/SUP], Jacob Haapala, Gabriela Vazquez-Benitez, Thomas G Boyce, Candace C Fuller, Matthew F Daley, Darios Getahun, Simon J Hambidge, Heather S Lipkind, Allison L Naleway, Jennifer C Nelson, Kimberly K Vesco, Eric S Weintraub, Joshua T B Williams, Ousseny Zerbo, Elyse O Kharbanda
Affiliations
- PMID: 37167612
- DOI: 10.1097/AOG.0000000000005241
In this multisite, observational, matched cohort study of more than 80,000 pregnant people, receipt of an mRNA monovalent coronavirus disease 2019 (COVID-19) booster vaccination in pregnancy was not associated with increased risk for thrombocytopenia, myocarditis, venous thromboembolism, ischemic stroke, or other serious adverse events within 21 or 42 days after booster vaccination. The mRNA monovalent COVID-19 booster in pregnancy was associated with an increased risk for medically attended malaise or fatigue within 7 days of vaccination (adjusted rate ratio [aRR] 3.64, 95% CI 2.42-5.48) and lymphadenopathy or lymphadenitis within 21 days (aRR 3.25, 95% CI 1.67-6.30) or 42 days (aRR 2.18, 95% CI 1.33-3.58) of vaccination. Our findings are consistent with prior evaluations of the primary COVID-19 vaccine series and are reassuring with respect to COVID-19 booster vaccination in pregnancy.